Payment overview · 2025
General Payments
$236.69
12 reported records · 7 companies
Healthcare provider profile · identity verified
Warren D Stacks, MD
Allopathic & Osteopathic Physicians|Family Medicine · WINSTON SALEM, NC · NPI 1740203090
Verified facts
What the public records show
CMS Open Payments records show Warren D Stacks, MD received $236.69 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 31.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Symbicort by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.91 | 31.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.53 | 18.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.29 | 17.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $27.49 | 11.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.50 | 8.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.01 | 6.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.96 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $236.69 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $44.53 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $40.29 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.23 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $27.49 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 56 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 44 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 604 | 161 |
| Atorvastatin Calcium | Atorvastatin Calcium | 578 | 161 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 432 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 304 | 86 |
| Lisinopril | Lisinopril | 283 | 76 |
| Gabapentin | Gabapentin | 281 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 244 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 73 |
| Furosemide | Furosemide | 207 | 63 |
| Alprazolam | Alprazolam | 200 | 26 |
| Omeprazole | Omeprazole | 190 | 53 |
| Metformin Hcl Er | Metformin Hcl | 175 | 50 |
| Eliquis | Apixaban | 173 | 29 |
| Trazodone Hcl | Trazodone Hcl | 170 | 52 |
| Alendronate Sodium | Alendronate Sodium | 162 | 56 |
| Meloxicam | Meloxicam | 147 | 40 |
| Metformin Hcl | Metformin Hcl | 142 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 35 |
| Prednisone | Prednisone | 123 | 88 |
| Celecoxib | Celecoxib | 119 | 35 |
| Allopurinol | Allopurinol | 115 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 114 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 32 |
| Mirtazapine | Mirtazapine | 99 | 24 |
| Potassium Chloride | Potassium Chloride | 98 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 11 |
| Carvedilol | Carvedilol | 84 | 26 |
| Losartan Potassium | Losartan Potassium | 84 | 26 |
| Clonazepam | Clonazepam | 78 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 25 |
| Ezetimibe | Ezetimibe | 77 | 27 |
| Famotidine | Famotidine | 77 | 21 |
| Pregabalin | Pregabalin | 77 | 29 |
| Valsartan | Valsartan | 76 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 70 | 19 |
| Ozempic | Semaglutide | 70 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 70 | 14 |
| Finasteride | Finasteride | 65 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 59 |
| Trulicity | Dulaglutide | 62 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 62 | 19 |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 59 | 52 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 19 |
| Farxiga | Dapagliflozin Propanediol | 56 | 19 |
| Sertraline Hcl | Sertraline Hcl | 56 | 16 |
| Lorazepam | Lorazepam | 55 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 53 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 15 |
| Buspirone Hcl | Buspirone Hcl | 52 | suppressed |
| Fenofibrate | Fenofibrate | 52 | 17 |
| Montelukast Sodium | Montelukast Sodium | 52 | 13 |
| Tramadol Hcl | Tramadol Hcl | 52 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Simvastatin | Simvastatin | 48 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 15 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Jardiance | Empagliflozin | 44 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Glipizide | Glipizide | 41 | 12 |
| Meclizine Hcl | Meclizine Hcl | 41 | 17 |
| Nabumetone | Nabumetone | 41 | 21 |
| Glimepiride | Glimepiride | 39 | 12 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 13 |
| Linzess | Linaclotide | 38 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 20 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 11 |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 33 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Torsemide | Torsemide | 34 | 11 |
| Azithromycin | Azithromycin | 33 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 31 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 27 |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 17 |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | 11 |
| Nitroglycerin | Nitroglycerin | 23 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Fluocinonide | Fluocinonide | 22 | 11 |
| Ramipril | Ramipril | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 16 |
| Rivastigmine | Rivastigmine Tartrate | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Entacapone | Entacapone | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | 11 |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Invokana | Canagliflozin | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Nucynta | Tapentadol Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $236.69 · 12 records | Novo Nordisk Inc | Dexcom G6 Transmitter, EVENITY, FARXIGA, JARDIANCE, LEQVIO, NEXLETOL, Ozempic | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error